Clinical characteristics of neuro-Behcet's disease in Japan: A multicenter retrospective analysis

Modern Rheumatology

Volumn 22, Issue 3, 2012, Pages 405-413

  Hirohata, Shunsei ^a   Kikuchi, Hirotoshi ^b   Sawada, Tetsuji ^c   Nagafuchi, Hiroko ^d   Kuwana, Masataka ^e   Takeno, Mitsuhiro ^f   Ishigatsubo, Yoshiaki ^f  

^a KITASATO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Beh et's disease; Central nervous system; Cerebrospinal fluid; Diagnostic criteria; Magnetic resonance imaging

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE;

ADULT; ARTICLE; BEHCET DISEASE; BRAIN ATROPHY; BRAIN STEM; CELL COUNT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEURO BEHCET DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY;

ADULT; BEHCET SYNDROME; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84865364906     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0533-5     Document Type: Article

References (23)

1. Hirohata S, Kikuchi H. Behçet's disease. Arthritis Res Ther. 2003;5:139-46.
2. Serdaroglu P. Behçet's disease and the nervous system. J Neurol. 1998;245:197-205.
3. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behçet's syndrome. Brain. 1999;122:2183-94.
4. Siva A, Altintas A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347-57.
5. Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: Evaluation of 200 patients. Brain. 1999;122:2171-82.
6. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro- Behcet's syndrome. Clin Immunol Immunopathol. 1997;82:12-7. (Pubitemid 27049067)
7. Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behçet's disease (Neuro-Behçet's syndrome). Curr Rheumatol Rev. 2007;3:297-303. (Pubitemid 350142063)
8. Siva A, Hirohata S. Behçet's syndrome and the nervous system. In: Yazici Y, Yazici H, editors. Behçet's syndrome. New York: Springer; 2010. p. 95-113.
9. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-80.
10. Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet's disease. Mod Rheumatol. 2007;17:81-2. (Pubitemid 46758776)
11. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586-9. (Pubitemid 30191596)
12. Dzudie A, Boissonnat P, Roussoulieres A, Cakmak, Mosbah K, Bejui FT, Obadia JF, Sebbag L. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: Should we withdraw or reduce cyclosporine?: Case reports. Transplant Proc. 2009;41:716-20.
13. Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behçet's uveitis: Is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(Suppl 50):S84-90.
14. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci. 1998;159:181-5. (Pubitemid 28384527)
15. Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behçet's syndrome. Headache. 2005;45:911-9.
16. Koçer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, et al. CNS involvement in neuro-Behçet's syndrome: An MR study. Am J Neuroradiol. 1999;20:1015-24. (Pubitemid 29536207)
17. Al-Araji A, Kidd DP. Neuro-Behçet's disease: Epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8: 192-204.
18. Hirohata S, Takeuchi A, Miyamoto T. Elevated levels of interleukin 6 in cerebrospinal fluid from patients with Neuro-Behçet's syndrome. In: O'Duffy JD, Kokmen E, editors. Behçet's disease. New York: Marcel Dekker; 1991. p. 369-76.
19. Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behcet's disease with infliximab: A case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis. 2007;66:136-7. (Pubitemid 46044876)
20. Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, KürtüncüM, et al. Interleukin-6 in neuro-Behçet's disease: Association with disease subsets and long-term outcome. Cytokine. 2008;44:373-6.
21. Haghighi AB, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, et al. CSF levels of cytokines in neuro-Behçet's disease. Clin Neurol Neurosurg. 2009;111:507-10.
22. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40:1735-9. (Pubitemid 20383141)
23. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005;128:988-1002. (Pubitemid 40675455)